Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In trading on Tuesday, shares of IRIDEX Corp. ( IRIX) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $13.541 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 67.6. A bullish investor could look at IRIX's 29.2 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of IRIX shares: Looking at the chart above, IRIX's low point in its 52 week range is $6.45 per share, with $16.64 as the 52 week high point — that compares with a last trade of $13.66.
HOST // Robert Powell
Retirement Planning Event
More from Stocks
Cause for Caution? Top Executives Selling Tilray Stock
It might not be time to panic yet about Tilray, but there's likely a problem ahead.
Google Unveils Stadia, Its Streaming Video Game Platform
Stadia will allow players to join games instantly without the need for a console.
With Tilray, You Won't Win Any Valuation Arguments
Short interest is back in the low single digits while Tilray still enjoys one of the smallest floats for a cannabis company.
Dow Trims Gains on Report China Is Pushing Back During Trade Talks
Stocks rise but come off highs Tuesday on reports that China may be pushing back against American trade talk demands.
Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat
Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.